ASND earnings date and last-quarter result: next report 2026-08-06, last quarter beat, P/E 26.95. Updated 2026-07-23.
Ascendis Pharma (ASND) Research Hub
Ascendis Pharma (ASND) trades on NASDAQ, DK in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 245.15 USD (+0.73%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E 26.95, market cap 15.67B. This hub links to the full technical, earnings and options research available for ASND.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, DK |
| Last close | 245.15 USD (+0.73%) |
| 52-week range | 218 USD – 282.15 USD |
| Trend regime | Range |
| 14-day RSI | 70.7 (Overbought) |
| Trailing P/E | 26.95 |
| Market cap | 15.67B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-06 |
Available research for ASND
Covered Call on ASND: how it works, illustrative setup around the real 245.15 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on ASND: how it works, illustrative setup around the real 245.15 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on ASND: how it works, illustrative setup around the real 245.15 USD price, max profit/loss, breakeven and when to use it. Educational.
ASND technical analysis: range, last 245.15 USD, RSI 70.7, 52w range 218 USD–282.15 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is ASND in?
Ascendis Pharma (ASND) is classified under Healthcare (Biotechnology), listed on NASDAQ, DK.
Is ASND in an uptrend or downtrend?
As of 2026-10-26, ASND is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is ASND's trailing P/E ratio?
ASND's trailing P/E is 26.95, with a market cap of 15.67B. See the earnings research page for full valuation detail.
When does ASND next report earnings?
ASND is next scheduled to report earnings on 2026-08-06.